ELISA ADAR Antibody, FITC

Quantity :50µL Clone Number: Aliases:136 kDa double-stranded RNA-binding protein antibody; 136kDa double stranded RNA binding protein antibody; Adar 1 antibody; ADAR antibody; Adar1 antibody; Adenosine deaminase acting on RNA 1 A antibody; Adenosine deaminase RNA specific 1 antibody; Adenosine deaminase RNA specific antibody; Adenosine deaminase that act on RNA antibody; AGS6 antibody; AV242451 antibody; Double stranded RNA specific adenosine deaminase antibody; Double-stranded RNA-specific adenosine deaminase antibody; Double-stranded RNA-specific editase Adar antibody; DRADA antibody; Dsh antibody; Dsrad antibody; DSRAD_ antibody; dsRNA adenosine deaminase antibody; EC 3.5.4.- antibody; G1P1 antibody; IFI 4 antibody; IFI-4 antibody; IFI4 antibody; Ifi4 protein antibody; Interferon induced protein 4 antibody; Interferon inducible protein 4 antibody; Interferon-inducible protein 4 antibody; K88DSRBP antibody; mZaADAR antibody; P136 antibody; Pre-mRNA adenosine deaminase antibody; RNA adenosine deaminase 1 antibody; RNA-editing deaminase 1 antibody; RNA-editing enzyme 1 antibody Product Type:Polyclonal Antibody Immunogen Species:Homo sapiens () UniProt ID:P55265 Immunogen:Recombinant Double-stranded RNA-specific adenosine deaminase protein (367-471AA) Raised in:Rabbit Reactivity: Tested Applications: Background:Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellµLar RNAs and can edit RNAs at mµLtiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellµLar RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins resµLts in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicµLar stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at mµLtiple sites. Enhances the replication of MV, VSV and HIV-1 throµgh an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. StimµLates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5\'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication. Clonality:Polyclonal Isotype:IgG Purification Method:>95%, Protein G purified Conjµgate:FITC Buffer:Preservative: 0.03% Proclin 300 Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 Form:Liquid Stroage:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. Target Names:ADAR Research Areas:Epigenetics and Nuclear Signaling; Microbiology